Objective: To investigate the relationship between the expression of multidrug resistance-associated protein (MRP) and clinicopathological factors and prognosis. Methods: The expression of MRP in 62 cases with non-sma...Objective: To investigate the relationship between the expression of multidrug resistance-associated protein (MRP) and clinicopathological factors and prognosis. Methods: The expression of MRP in 62 cases with non-small cell lung cancer (NSCLC) was detected using immunohistochemistry method. The expression of MRP in 30 cases of NSCLC and corresponding normal lung tissues were detected using immunohistochemistry and Western Blot. Results: this study of tumor tissues confirmed the plasma membrane and/or cytoplasm locations of MRP. There was apparent difference between normal lung tissues and NSCLC in MRP. The survival analysis of 62 NSCLC showed that the mean survival time of the patients with negative MRP expression was 69.8117.41 months and that of patients with positive MRP expression, 25.384.46 months. Log-rank test suggested that the difference between them was significant (P=0.0156). It was also found that in squamous cell lung cancer the statistically significant difference between the mean survival time of patients with positive MRP expression and those with negative MRP expression (P=0.0153). Multivariate Cox model analysis suggested that the survival time was significantly related to expression of MRP (P=0.035) and lymphatic metastasis (P=0.038). Conclusion: MRP expression in NSCLC is significantly higher compared with normal lung tissues. The mean survival time of patients with negative MRP was relative longer and expression of MRP was an independent factor for prognosis.展开更多
Objective: To investigate the effects of neoadjuvant chemotherapy on the expression of drug resistance genes, multidrug resistance-1 (MDR1) and multidrug resistance-associated protein (MRP), in patients with primary b...Objective: To investigate the effects of neoadjuvant chemotherapy on the expression of drug resistance genes, multidrug resistance-1 (MDR1) and multidrug resistance-associated protein (MRP), in patients with primary breast cancer. Methods: MDR1 and MRP expression were detected by semi-quantitative RT-PCR in 20 patients with primary breast cancer, before and after chemotherapy. Results: Before chemotherapy, MDR1 and MRP expression can be detected in 15 cases (75%) and 18 cases (90%) respectively. After chemotherapy, expression of MDR1 is not significantly different from that before chemotherapy, but expression of MRP is significantly different from that before chemotherapy. Conclusion: Expression of drug resistance gene MRP, but not MDR1, is enhanced in patients with primary breast cancer submitted to neoadjuvant chemotherapy.展开更多
目的:研究多药耐药相关蛋白（Multidrug resistance-associated protein 1,MRP1）在乳腺癌组织中的表达,评估其在乳腺癌预后中的作用。方法:采用免疫组织化学方法（IHC）检测47例手术切除的乳腺癌组织中MRP1的表达,并分析其与临床、...目的:研究多药耐药相关蛋白（Multidrug resistance-associated protein 1,MRP1）在乳腺癌组织中的表达,评估其在乳腺癌预后中的作用。方法:采用免疫组织化学方法（IHC）检测47例手术切除的乳腺癌组织中MRP1的表达,并分析其与临床、病理特征的关系及对预后的影响。结果:（1）MRP1在乳腺癌组织中的阳性表达率为85.1％（40/47例）,其中高表达者占53.2％（25/47例）;（2）腋淋巴结阳性者MRP1表达水平明显高于腋淋巴结阴性者（P<0.05）,MRP1表达与月经状况、肿瘤大小、组织分级和激素受体状况均无关（P>0.05）;（3）Kaplan-Meier生存分析结果表明MRP1表达与无病生存期明显相关（P<0.05）,但和总生存期无关（P>0.05）;（4）Cox单因素分析显示肿瘤大小和MRP1表达与无病生存期明显相关（P<0.05）,但仅有肿瘤大小和总生存期明显相关（P<0.05）;而多因素分析却显示只有腋淋巴结转移和无病生存期（P<0.01）和总生存期（P<0.05）明显相关。结论:MRP1在乳腺癌组织中具有较高的表达水平,与乳腺癌患者的无病生存期有关,而与总生存期无关。展开更多
To improve catalytic activity of ribozyme on its substrate, the multi-ribozyme expression system was designed and constructed from 20 cis-acting hammerhead ribozymes undergoing self-cleavage with 10 trans-acting hamme...To improve catalytic activity of ribozyme on its substrate, the multi-ribozyme expression system was designed and constructed from 20 cis-acting hammerhead ribozymes undergoing self-cleavage with 10 trans-acting hammerhead ribozymes inserted alternatively regularly and the plasmid of pGEM-MDR1/MRP1 used to transcribe the MDR1/MRPl（196/210） substrate containing double target sites was also constructed by DNA recombination. Endonuclease digestion analysis and DNA sequencing indicate all the recombinant plasmids were correct. The clea- vage activities were evaluated for the multi-ribozyme expression system on the MDR1/MRP1 substrate in the cell free system. The results demonstrate that the cis-acting hammerhead ribozymes in the multi-ribozyme expression system were able to cleave themselves and the 72 nt of 196Rz and the 71 nt of 210Rz trans-acting hammerhead ribozymes were liberated effectively, and the trans-acting hammerhead ribozymes released were able to act on the MDR1/MRP1 double target RNA substrate and cleave the target RNA at specific sites effectively. The multi- ribozyme expression system of the [Coat＇A196Rz/Coat＇B210Rz]5 is more significantly superior to that of the [Coat＇A 196Rz/Coat＇B210Rz] 1 in cleavage of RNA substrate. The fractions cleaved by [Coat＇A 196Rz/Coat＇B210Rz]5 on the MDR1/MRP1 substrate for 8 h at observed temperatures showed no marked difference. The studies of Mg^2＋ on cleavage efficiency indicate that cleavage reaction is dependent on Mg^2＋ ions concentration. The plot of lg（kobs） vs. lgc（Mg^2＋） displays a linear relationship between 2.5 mmol/L and 20 mmol/L Mg^2＋. It suggests that Mg^2＋ ions play a crucial role in multi-ribozyme cleavage on the substrate.展开更多
目的研究多药耐药相关蛋白(Multidrug resistance-associated protein 1,MRP1)在乳腺癌组织中的表达,评估其在乳腺癌预后中的作用。方法采用免疫组织化学方法(lmmunohistochemistry,IHC)检测60例手术切除的乳腺癌组织中MRP1的表达,并分...目的研究多药耐药相关蛋白(Multidrug resistance-associated protein 1,MRP1)在乳腺癌组织中的表达,评估其在乳腺癌预后中的作用。方法采用免疫组织化学方法(lmmunohistochemistry,IHC)检测60例手术切除的乳腺癌组织中MRP1的表达,并分析其与临床、病理特征的关系及对预后的影响。结果(1)MRP1在乳腺癌组织中的阳性表达率为85.0%(51/60例),其中高表达者32例(53.3%);(2)腋淋巴结转移阳性者MRP1表达水平明显高于腋淋巴结转移阴性者(P<0.05),MRP1表达与月经状况、肿瘤大小、组织分级和激素受体状况均无关(P>0.05);(3)Kaplan-Meier生存分析结果表明:MRP1表达与无病生存期明显相关(P<0.05),但和总生存期无关(P>0.05);(4)COX多因素分析显示肿瘤大小、腋淋巴结转移和雌激素受体状况仍是影响无病生存期和总生存期的重要因素(P<0.05),同时MRP1表达与和无病生存期和总生存期均无关(P>0.05)。结论MRP1在乳腺癌组织中具有较高的表达水平,但与乳腺癌患者预后无关。展开更多
文摘Objective: To investigate the relationship between the expression of multidrug resistance-associated protein (MRP) and clinicopathological factors and prognosis. Methods: The expression of MRP in 62 cases with non-small cell lung cancer (NSCLC) was detected using immunohistochemistry method. The expression of MRP in 30 cases of NSCLC and corresponding normal lung tissues were detected using immunohistochemistry and Western Blot. Results: this study of tumor tissues confirmed the plasma membrane and/or cytoplasm locations of MRP. There was apparent difference between normal lung tissues and NSCLC in MRP. The survival analysis of 62 NSCLC showed that the mean survival time of the patients with negative MRP expression was 69.8117.41 months and that of patients with positive MRP expression, 25.384.46 months. Log-rank test suggested that the difference between them was significant (P=0.0156). It was also found that in squamous cell lung cancer the statistically significant difference between the mean survival time of patients with positive MRP expression and those with negative MRP expression (P=0.0153). Multivariate Cox model analysis suggested that the survival time was significantly related to expression of MRP (P=0.035) and lymphatic metastasis (P=0.038). Conclusion: MRP expression in NSCLC is significantly higher compared with normal lung tissues. The mean survival time of patients with negative MRP was relative longer and expression of MRP was an independent factor for prognosis.
文摘Objective: To investigate the effects of neoadjuvant chemotherapy on the expression of drug resistance genes, multidrug resistance-1 (MDR1) and multidrug resistance-associated protein (MRP), in patients with primary breast cancer. Methods: MDR1 and MRP expression were detected by semi-quantitative RT-PCR in 20 patients with primary breast cancer, before and after chemotherapy. Results: Before chemotherapy, MDR1 and MRP expression can be detected in 15 cases (75%) and 18 cases (90%) respectively. After chemotherapy, expression of MDR1 is not significantly different from that before chemotherapy, but expression of MRP is significantly different from that before chemotherapy. Conclusion: Expression of drug resistance gene MRP, but not MDR1, is enhanced in patients with primary breast cancer submitted to neoadjuvant chemotherapy.
文摘目的:研究多药耐药相关蛋白（Multidrug resistance-associated protein 1,MRP1）在乳腺癌组织中的表达,评估其在乳腺癌预后中的作用。方法:采用免疫组织化学方法（IHC）检测47例手术切除的乳腺癌组织中MRP1的表达,并分析其与临床、病理特征的关系及对预后的影响。结果:（1）MRP1在乳腺癌组织中的阳性表达率为85.1％（40/47例）,其中高表达者占53.2％（25/47例）;（2）腋淋巴结阳性者MRP1表达水平明显高于腋淋巴结阴性者（P<0.05）,MRP1表达与月经状况、肿瘤大小、组织分级和激素受体状况均无关（P>0.05）;（3）Kaplan-Meier生存分析结果表明MRP1表达与无病生存期明显相关（P<0.05）,但和总生存期无关（P>0.05）;（4）Cox单因素分析显示肿瘤大小和MRP1表达与无病生存期明显相关（P<0.05）,但仅有肿瘤大小和总生存期明显相关（P<0.05）;而多因素分析却显示只有腋淋巴结转移和无病生存期（P<0.01）和总生存期（P<0.05）明显相关。结论:MRP1在乳腺癌组织中具有较高的表达水平,与乳腺癌患者的无病生存期有关,而与总生存期无关。
基金Supported by Fund of Shenzhen Bureau of Science and Technology, China(No.20008).
文摘To improve catalytic activity of ribozyme on its substrate, the multi-ribozyme expression system was designed and constructed from 20 cis-acting hammerhead ribozymes undergoing self-cleavage with 10 trans-acting hammerhead ribozymes inserted alternatively regularly and the plasmid of pGEM-MDR1/MRP1 used to transcribe the MDR1/MRPl（196/210） substrate containing double target sites was also constructed by DNA recombination. Endonuclease digestion analysis and DNA sequencing indicate all the recombinant plasmids were correct. The clea- vage activities were evaluated for the multi-ribozyme expression system on the MDR1/MRP1 substrate in the cell free system. The results demonstrate that the cis-acting hammerhead ribozymes in the multi-ribozyme expression system were able to cleave themselves and the 72 nt of 196Rz and the 71 nt of 210Rz trans-acting hammerhead ribozymes were liberated effectively, and the trans-acting hammerhead ribozymes released were able to act on the MDR1/MRP1 double target RNA substrate and cleave the target RNA at specific sites effectively. The multi- ribozyme expression system of the [Coat＇A196Rz/Coat＇B210Rz]5 is more significantly superior to that of the [Coat＇A 196Rz/Coat＇B210Rz] 1 in cleavage of RNA substrate. The fractions cleaved by [Coat＇A 196Rz/Coat＇B210Rz]5 on the MDR1/MRP1 substrate for 8 h at observed temperatures showed no marked difference. The studies of Mg^2＋ on cleavage efficiency indicate that cleavage reaction is dependent on Mg^2＋ ions concentration. The plot of lg（kobs） vs. lgc（Mg^2＋） displays a linear relationship between 2.5 mmol/L and 20 mmol/L Mg^2＋. It suggests that Mg^2＋ ions play a crucial role in multi-ribozyme cleavage on the substrate.
文摘目的研究多药耐药相关蛋白(Multidrug resistance-associated protein 1,MRP1)在乳腺癌组织中的表达,评估其在乳腺癌预后中的作用。方法采用免疫组织化学方法(lmmunohistochemistry,IHC)检测60例手术切除的乳腺癌组织中MRP1的表达,并分析其与临床、病理特征的关系及对预后的影响。结果(1)MRP1在乳腺癌组织中的阳性表达率为85.0%(51/60例),其中高表达者32例(53.3%);(2)腋淋巴结转移阳性者MRP1表达水平明显高于腋淋巴结转移阴性者(P<0.05),MRP1表达与月经状况、肿瘤大小、组织分级和激素受体状况均无关(P>0.05);(3)Kaplan-Meier生存分析结果表明:MRP1表达与无病生存期明显相关(P<0.05),但和总生存期无关(P>0.05);(4)COX多因素分析显示肿瘤大小、腋淋巴结转移和雌激素受体状况仍是影响无病生存期和总生存期的重要因素(P<0.05),同时MRP1表达与和无病生存期和总生存期均无关(P>0.05)。结论MRP1在乳腺癌组织中具有较高的表达水平,但与乳腺癌患者预后无关。
